NCT06267092 - A Study of How CagriSema Works on Appetite in People With Excess Body Weight | Biotech Hunter

Enrollment

164

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

April 7, 2025

Study Completion Date

December 22, 2025

Conditions

OverweightObesity

Interventions

OTHER

No treatment given

Participants will not get any medicine during this study.

DRUG

Cagrilintide and Semaglutide

Participants will receive subcutaneous (s.c.) injections of Cagrilintide and Semaglutide.

DRUG

Placebo

Participants will receive subcutaneous (s.c.) injections of placebo matched to Cagrilintide and Semaglutide.

Trial Locations (1)

Charité Research Organisation GmbH, Berlin